Discovery of Potent and Selective Covalent Inhibitors of HER2 WT and HER2 YVMA
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c00978 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Erik J Hicken und 21 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Boulder Research and Development, Boulder, Colorado 80301, United States. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Protein Kinase Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
HER2 overexpression and amplification have been identified as oncogenic drivers, and the development of therapies to treat tumors harboring these markers has received considerable attention. Activation of HER2 signaling and subsequent cell growth can also be induced by HER2 mutations, including the common YVMA insertion in exon 20 within the kinase domain. Enhertu is currently the only approved treatment for HER2 mutant tumors in NSCLC. TKIs tested in this space have suffered from off-target activity, primarily due to EGFRWT inhibition or attenuated activity against HER2 mutants. The goal of this work was to identify a TKI that would provide robust inhibition of oncogenic HER2WT and HER2 mutants while sparing EGFRWT activity. Herein, we describe the development of a potent, covalent inhibitor of HER2WT and the YVMA insertion mutant while providing oral bioavailability and avoiding the inhibition of EGFRWT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pfizer Boulder Research and Development, Boulder, Colorado 80301, United States.
ORCID-Profile: Erik J Hicken, Russell Shelp, Courtney E Wise
Zitieren
APA
Hicken, E. J., Brown, K., Dwulet, N. C., Gaudino, J. J., Hansen, E. P., Hartley, D. P., Kowalski, J. P., Laird, E. R., Lazzara, N. C., Li, B., Mou, T. C., Mutryn, M. F., Oko, L., Pajk, S., Pipal, R. W., Rosen, R. Z., Shelp, R., Singh, A., Wang, J., …, & Wong, J. Y. (2024). Discovery of Potent and Selective Covalent Inhibitors of HER2 WT and HER2 YVMA. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00978
Vancouver
Hicken EJ, Brown K, Dwulet NC, Gaudino JJ, Hansen EP, Hartley DP, et al. Discovery of Potent and Selective Covalent Inhibitors of HER2 WT and HER2 YVMA. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00978
BibTeX
@article{Hicken2024,
author = {Hicken, Erik J and Brown, Karin and Dwulet, Natalie C and Gaudino, John J and Hansen, Erik P and Hartley, Dylan P and Kowalski, John P and Laird, Ellen R and Lazzara, Nicholas C and Li, Bin and Mou, Tung-Chung and Mutryn, Marie F and Oko, Lauren and Pajk, Spencer and Pipal, Robert W and Rosen, Rachel Z and Shelp, Russell and Singh, Anurag and Wang, Jing and Wise, Courtney E and Wong, Christina and Wong, Jim Y},
title = {Discovery of Potent and Selective Covalent Inhibitors of HER2 WT and HER2 YVMA},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c00978}
}
EUVIMED